Search

Your search keyword '"Matsui, Naoko"' showing total 324 results
Start Over Author "Matsui, Naoko"
324 results on '"Matsui, Naoko"'

2. Complex hereditary peripheral neuropathies caused by novel variants in mitochondrial-related nuclear genes

Author

Hiramatsu, Yu, Okamoto, Yuji, Yoshimura, Akiko, Yuan, Jun-Hui, Ando, Masahiro, Higuchi, Yujiro, Hashiguchi, Akihiro, Matsuura, Eiji, Nozaki, Fumihito, Kumada, Tomohiro, Murayama, Kei, Suzuki, Mikiya, Yamamoto, Yuki, Matsui, Naoko, Miyazaki, Yoshimichi, Yamaguchi, Masamitsu, Suzuki, Youji, Mitsui, Jun, Ishiura, Hiroyuki, Tanaka, Masaki, Morishita, Shinichi, Nishino, Ichizo, Tsuji, Shoji, and Takashima, Hiroshi

Published
2022
Full Text
View/download PDF

3. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities

Author

Yamada, Yosuke, Belharazem-Vitacolonnna, Djeda, Bohnenberger, Hanibal, Weiß, Christel, Matsui, Naoko, Kriegsmann, Mark, Kriegsmann, Katharina, Sinn, Peter, Simon-Keller, Katja, Hamilton, Gerhard, Graeter, Thomas, Preissler, Gerhard, Ott, German, Schölch, Sebastian, Nakajima, Naoki, Yoshizawa, Akihiko, Haga, Hironori, Date, Hiroshi, Thomas, Roman K., Petrini, Iacopo, Giaccone, Giuseppe, Ströbel, Philipp, and Marx, Alexander

Published
2022
Full Text
View/download PDF

4. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.

Author

Ohba, Akihiro, Morizane, Chigusa, Kawamoto, Yasuyuki, Komatsu, Yoshito, Ueno, Makoto, Kobayashi, Satoshi, Ikeda, Masafumi, Sasaki, Mitsuhito, Furuse, Junji, Okano, Naohiro, Hiraoka, Nobuyoshi, Yoshida, Hiroshi, Kuchiba, Aya, Sadachi, Ryo, Nakamura, Kenichi, Matsui, Naoko, Nakamura, Yoshiaki, Okamoto, Wataru, Yoshino, Takayuki, and Okusaka, Takuji

Published
2024
Full Text
View/download PDF

6. High stability of the ferroelectricity against hydrogen gas in (Al,Sc)N thin films.

Author

Sun, Nana, Okamoto, Kazuki, Yasuoka, Shinnosuke, Doko, Soshun, Matsui, Naoko, Irisawa, Toshikazu, Tsunekawa, Koji, Katase, Takayoshi, Koganezawa, Tomoyuki, Nakatani, Tomotaka, Kumara, Rosantha, Sakata, Osami, and Funakubo, Hiroshi

Subjects
THIN films, FERROELECTRICITY, FERROELECTRIC crystals, TANTALUM, TIN, CRYSTAL structure, HYDROGEN
Abstract

The changes in the crystal structure and ferroelectric properties of (Al0.8Sc0.2)N films sandwiched between Pt and TiN electrodes were investigated by subjecting the films to post-heat-treatment at various temperatures up to 600 °C in both H2 and Ar gases. The remanent polarization underwent slight change, whereas the coercive field strengthened by approximately 9% as a result of the post-heat-treatment up to 600 °C irrespective of the atmosphere and electrode material. This change is much smaller than that reported for ferroelectric (Hf,Zr)O2 films as well as for Pb(Zr,Ti)O3 and SrBi2Ta2O9 films for a wide temperature range from 400 to 600 °C and is almost independent of the Pt and TiN electrodes. The high stability of (Al,Sc)N films with both Pt and TiN electrodes under H2 atmosphere is highly promising to stabilize the properties through the device fabrication process. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial

Author

Misawa, S, Kuwabara, S, Sato, Y, Yamaguchi, N, Nagashima, K, Katayama, K, Sekiguchi, Y, Iwai, Y, Amino, H, Suichi, T, Yokota, T, Nishida, Y, Kanouchi, T, Kohara, N, Kawamoto, M, Ishii, J, Kuwahara, M, Suzuki, H, Hirata, K, Kokubun, N, Masuda, R, Kaneko, J, Yabe, I, Sasaki, H, Kaida, K, Takazaki, H, Suzuki, N, Suzuki, S, Nodera, H, Matsui, N, Tsuji, S, Koike, H, Yamasaki, R, Kusunoki, S, Nagashima, T, Shimizu, T, Hirotani, M, Kadoya, M, Nakahara, J, Shimizu, J, Tanaka, M, Sobue, G, Katsuno, M, Yamaguchi, H, Ogata, H, Misawa, Sonoko, Kuwabara, Satoshi, Sato, Yasunori, Yamaguchi, Nobuko, Nagashima, Kengo, Katayama, Kanako, Sekiguchi, Yukari, Iwai, Yuta, Amino, Hiroshi, Suichi, Tomoki, Yokota, Takanori, Nishida, Yoichiro, Kanouchi, Tadashi, Kohara, Nobuo, Kawamoto, Michi, Ishii, Junko, Kuwahara, Motoi, Suzuki, Hidekazu, Hirata, Koichi, Kokubun, Norito, Masuda, Ray, Kaneko, Juntaro, Yabe, Ichiro, Sasaki, Hidenao, Kaida, Ken-ichi, Takazaki, Hiroshi, Suzuki, Norihiro, Suzuki, Shigeaki, Nodera, Hiroyuki, Matsui, Naoko, Tsuji, Shoji, Koike, Haruki, Yamasaki, Ryo, and Kusunoki, Susumu

Published
2018
Full Text
View/download PDF

10. Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table S3A-B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

13. Data from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

14. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, additional, Kojima, Yuki, additional, Sudo, Kazuki, additional, Okuma, Hitomi Sumiyoshi, additional, Shimoi, Tatsunori, additional, Ichikawa, Hitoshi, additional, Kohsaka, Shinji, additional, Sadachi, Ryo, additional, Hirakawa, Akihiro, additional, Yoshida, Akihiko, additional, Ando, Reiko Makihara, additional, Ueno, Toshihide, additional, Yanagaki, Mitsuru, additional, Matsui, Naoko, additional, Nakamura, Kenichi, additional, Yamamoto, Noboru, additional, and Yonemori, Kan, additional

Published
2023
Full Text
View/download PDF

15. The updated retrospective questionnaire study of sporadic inclusion body myositis in Japan

Author

Suzuki, Naoki, Mori-Yoshimura, Madoka, Yamashita, Satoshi, Nakano, Satoshi, Murata, Ken-ya, Mori, Megumi, Inamori, Yukie, Matsui, Naoko, Kimura, En, Kusaka, Hirofumi, Kondo, Tomoyoshi, Ito, Hidefumi, Higuchi, Itsuro, Hashiguchi, Akihiro, Nodera, Hiroyuki, Kaji, Ryuji, Tateyama, Maki, Izumi, Rumiko, Ono, Hiroya, Kato, Masaaki, Warita, Hitoshi, Takahashi, Toshiaki, Nishino, Ichizo, and Aoki, Masashi

Published
2019
Full Text
View/download PDF

27. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Author

Ohba, Akihiro, primary, Morizane, Chigusa, additional, Kawamoto, Yasuyuki, additional, Komatsu, Yoshito, additional, Ueno, Makoto, additional, Kobayashi, Satoshi, additional, Ikeda, Masafumi, additional, Sasaki, Mitsuhito, additional, Furuse, Junji, additional, Okano, Naohiro, additional, Hiraoka, Nobuyoshi, additional, Yoshida, Hiroshi, additional, Kuchiba, Aya, additional, Sadachi, Ryo, additional, Nakamura, Kenichi, additional, Matsui, Naoko, additional, Nakamura, Yoshiaki, additional, Okamoto, Wataru, additional, Yoshino, Takayuki, additional, and Okusaka, Takuji, additional

Published
2022
Full Text
View/download PDF

28. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial

Author

Ohba, Akihiro, primary, Morizane, Chigusa, additional, Ueno, Makoto, additional, Kobayashi, Satoshi, additional, Kawamoto, Yasuyuki, additional, Komatsu, Yoshito, additional, Ikeda, Masafumi, additional, Sasaki, Mitsuhito, additional, Okano, Naohiro, additional, Furuse, Junji, additional, Hiraoka, Nobuyoshi, additional, Yoshida, Hiroshi, additional, Kuchiba, Aya, additional, Sadachi, Ryo, additional, Nakamura, Kenichi, additional, Matsui, Naoko, additional, Nakamura, Yoshiaki, additional, Okamoto, Wataru, additional, Yoshino, Takayuki, additional, and Okusaka, Takuji, additional

Published
2022
Full Text
View/download PDF

29. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities

Author

40742622, 10252462, 60252962, Yamada, Yosuke, Belharazem-Vitacolonnna, Djeda, Bohnenberger, Hanibal, Weiß, Christel, Matsui, Naoko, Kriegsmann, Mark, Kriegsmann, Katharina, Sinn, Peter, Simon-Keller, Katja, Hamilton, Gerhard, Graeter, Thomas, Preissler, Gerhard, Ott, German, Schölch, Sebastian, Nakajima, Naoki, Yoshizawa, Akihiko, Haga, Hironori, Date, Hiroshi, Thomas, Roman K., Petrini, Iacopo, Giaccone, Giuseppe, Ströbel, Philipp, Marx, Alexander, 40742622, 10252462, 60252962, Yamada, Yosuke, Belharazem-Vitacolonnna, Djeda, Bohnenberger, Hanibal, Weiß, Christel, Matsui, Naoko, Kriegsmann, Mark, Kriegsmann, Katharina, Sinn, Peter, Simon-Keller, Katja, Hamilton, Gerhard, Graeter, Thomas, Preissler, Gerhard, Ott, German, Schölch, Sebastian, Nakajima, Naoki, Yoshizawa, Akihiko, Haga, Hironori, Date, Hiroshi, Thomas, Roman K., Petrini, Iacopo, Giaccone, Giuseppe, Ströbel, Philipp, and Marx, Alexander

Abstract

Tuft cells are chemosensory epithelial cells in the respiratory tract and several other organs. Recent studies revealed tuft cell-like gene expression signatures in some pulmonary adenocarcinomas, squamous cell carcinomas (SQCC), small cell carcinomas (SCLC), and large cell neuroendocrine carcinomas (LCNEC). Identification of their similarities could inform shared druggable vulnerabilities. Clinicopathological features of tuft cell-like (tcl) subsets in various lung cancer histotypes were studied in two independent tumor cohorts using immunohistochemistry (n = 674 and 70). Findings were confirmed, and additional characteristics were explored using public datasets (RNA seq and immunohistochemical data) (n = 555). Drug susceptibilities of tuft cell-like SCLC cell lines were also investigated. By immunohistochemistry, 10–20% of SCLC and LCNEC, and approximately 2% of SQCC expressed POU2F3, the master regulator of tuft cells. These tuft cell-like tumors exhibited “lineage ambiguity” as they co-expressed NCAM1, a marker for neuroendocrine differentiation, and KRT5, a marker for squamous differentiation. In addition, tuft cell-like tumors co-expressed BCL2 and KIT, and tuft cell-like SCLC and LCNEC, but not SQCC, also highly expressed MYC. Data from public datasets confirmed these features and revealed that tuft cell-like SCLC and LCNEC co-clustered on hierarchical clustering. Furthermore, only tuft cell-like subsets among pulmonary cancers significantly expressed FOXI1, the master regulator of ionocytes, suggesting their bidirectional but immature differentiation status. Clinically, tuft cell-like SCLC and LCNEC had a similar prognosis. Experimentally, tuft cell-like SCLC cell lines were susceptible to PARP and BCL2 co-inhibition, indicating synergistic effects. Taken together, pulmonary tuft cell-like cancers maintain histotype-related clinicopathologic characteristics despite overlapping unique molecular features. From a therapeutic perspective, identification of tuft

Published
2022

41. Diagnostic spectrum of multifocal motor neuropathy

Author

Matsui, Naoko, Miyashiro, Ai, Shimatani, Yoshimitsu, Nodera, Hiroyuki, Izumi, Yuishin, Kuwabara, Satoshi, Baba, Masayuki, Komori, Tetsuo, Sonoo, Masahiro, Mezaki, Takahiro, Kawamata, Jun, Hitomi, Takefumi, Imai, Tomihiro, Kohara, Nobuo, Arimura, Kimiyoshi, Arisawa, Kokichi, Kusunoki, Susumu, and Kaji, Ryuji

Published
2013
Full Text
View/download PDF

42. Effect of antioxidant supplementation on skeletal muscle and metabolic profile in aging mice

Author

Tsukamoto-Sen, Sakuka, primary, Kawakami, Shinpei, additional, Maruki-Uchida, Hiroko, additional, Ito, Ryouichi, additional, Matsui, Naoko, additional, Komiya, Yuki, additional, Mita, Yoshitaka, additional, Morisasa, Mizuki, additional, Goto-Inoue, Naoko, additional, Furuichi, Yasuro, additional, Manabe, Yasuko, additional, Morita, Minoru, additional, and Fujii, Nobuharu L., additional

Published
2021
Full Text
View/download PDF

46. Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.

Author

Ohba, Akihiro, primary, Morizane, Chigusa, additional, Ueno, Makoto, additional, Kobayashi, Satoshi, additional, Kawamoto, Yasuyuki, additional, Komatsu, Yoshito, additional, Ikeda, Masafumi, additional, Sasaki, Mitsuhito, additional, Okano, Naohiro, additional, Furuse, Junji, additional, Hiraoka, Nobuyoshi, additional, Yoshida, Hiroshi, additional, Kuchiba, Aya, additional, Ogawa, Gakuto, additional, Nakamura, Kenichi, additional, Matsui, Naoko, additional, Nakamura, Yoshiaki, additional, Okamoto, Wataru, additional, Yoshino, Takayuki, additional, and Okusaka, Takuji, additional

Published
2020
Full Text
View/download PDF

48. 疾患活動性の高い重症筋無力症患者の胸腺ではプラズマブラストが増加している

Author

Yamamoto, Yohei, Matsui, Naoko, Uzawa, Akiyuki, Ozawa, Yukiko, Kanai, Tetsuya, Oda, Fumiko, Kondo, Hiroyuki, Ohigashi, Izumi, Takizawa, Hiromitsu, Kondo, Kazuya, Sugano, Mikio, Kitaichi, Takashi, Hata, Hiroki, Kaji, Ryuji, Kuwabara, Satoshi, Yamamura, Takashi, and Izumi, Yuishin

Subjects
B cell, Myasthenia Gravis, Thymectomy, Tfh cell, Plasmablast
Abstract

Background and Objectives To investigate intrathymic B lymphopoiesis in patients with myasthenia gravis (MG) and explore thymus pathology associated with clinical impact. Methods Thymic lymphocytes from 15 young patients without MG, 22 adult patients without MG, 14 patients with MG without thymoma, and 11 patients with MG with thymoma were subjected to flow cytometry analysis of T follicular helper (Tfh), naive B, memory B, plasmablasts, CD19+B220high thymic B cells, B-cell activating factor receptor, and C-X-C chemokine receptor 5 (CXCR5). Peripheral blood mononuclear cells of 16 healthy subjects and 21 untreated patients with MG were also analyzed. Immunologic values were compared, and correlations between relevant values and clinical parameters were evaluated. Results The frequencies of circulating and intrathymic plasmablasts were significantly higher in patients with MG than controls. On the other hand, the frequency of CD19+B220high thymic B cells was not increased in MG thymus. We observed a significant increase in CXCR5 expression on plasmablasts in MG thymus and an increased frequency of intrathymic plasmablasts that was correlated with preoperative disease activity. The frequency of intrathymic Tfh cells was significantly lower in patients who received immunosuppressive (IS) therapy than those without IS therapy. However, there was no significant difference in the frequency of intrathymic plasmablasts irrespective of IS therapy. Discussion Our findings confirmed a correlation between increased frequency of intrathymic plasmablasts and disease activity before thymectomy. We postulate that activated intrathymic plasmablasts endow pathogenic capacity in MG.

Published
2021

50. Prediction of improvement after extended thymectomy in non-thymomatous myasthenia gravis patients

Author

Yoshida, Mitsuteru, Kondo, Kazuya, Matsui, Naoko, Izumi, Yuishinn, Bando, Yoshimi, Yokoishi, Michihiro, Kajiura, Kouichirou, Tangoku, Akira, Yoshida, Mitsuteru, Kondo, Kazuya, Matsui, Naoko, Izumi, Yuishinn, Bando, Yoshimi, Yokoishi, Michihiro, Kajiura, Kouichirou, and Tangoku, Akira

Abstract

Background It is popularly believed that myasthenia gravis (MG) patients show acetylcholine receptor antibody (AChRAb) production associated with the thymus (germinal centers, approximately 80%). It has been suggested that thymectomy can remove the area of autoantibody production. This study aimed to determine whether the solid volume of the thymus calculated using three-dimensional (3D) imaging could be used to predict the efficacy of thymectomy. Additionally, the study assessed the relationships of the solid volume with germinal centers, change in the serum AChRAb level, postoperative MG improvement, and prednisolone (PSL) dose reduction extent. Methods This retrospective study included 12 consecutive non-thymomatous MG patients (9 female and 3 male patients), who underwent extended thymectomy at our institution over the last 10 years. The mean patient age was 43.3 ± 14.2 years (range, 12–59 years). The study assessed the number of germinal centers per unit area, change in the serum AChRAb level, postoperative MG improvement, PSL dose reduction extent, and solid volume of the thymus. Results The number of germinal centers per unit area was significantly correlated with the solid volume of the thymus. The PSL dose reduction extent tended to be correlated with the solid volume. Conclusions Our findings suggest that the solid volume of the thymus can possibly predict steroid dose reduction. Additionally, the solid volume of the thymus in 3D images is the most important indicator for predicting the efficacy of extended thymectomy.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results